share_log

ANGLE Presents Two Posters at EACR

ANGLE Presents Two Posters at EACR

ANGLE在EACR会议上展示了两幅海报。
Accesswire ·  11/13 15:00

PARSORTIX-BASED ASSAYS SHOWCASED AT THE EUROPEAN ASSOCIATION FOR CANCER RESEARCH LIQUID BIOPSIES CONFERENCE

基于PARSORTIX的检测在欧洲抗癌医药液体活检会议上展示

Two posters highlight the importance of epitope-independent CTC enrichment and molecular characterisation of CTCs

两张海报突出了表位独立的CTC富集和CTC的分子特征化的重要性

GUILDFORD, SURREY / ACCESSWIRE / November 13, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce its participation at the European Association for Cancer Research (EACR) Liquid Biopsies Conference being held in Lyon, France from 12 to 14 November 2024.

吉尔福德,萨里 / ACCESSWIRE / 2024年11月13日 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY),一家世界领先的液体活检公司,提供用于研究、药物开发和临床肿瘤学的创新循环肿瘤细胞(CTC)解决方案,很高兴宣布参加将于2024年11月12日至14日在法国里昂举行的欧洲抗癌医药(EACR)液体活检会议。

ANGLE presented two posters at the EACR Liquid Biopsies Conference:

ANGLE在EACR液体活检会议上展示了两张海报:

1. Combined epitope-independent microfluidic isolation and advanced staining of circulating tumour cells isolated from metastatic prostate cancer blood samples

1. 从转移性前列腺癌血液样本中分离的循环肿瘤细胞的结合表位独立微流体分离和先进染色

This poster presentation reports on the utility of combining ANGLE's Parsortix system for CTC capture with the Portrait+ CTC staining kit for CTC detection and phenotypic characterisation. This workflow provides an efficient, standardised solution for the characterisation of multiple CTC phenotypes (epithelial, mesenchymal and those transitioning).

该海报演示报告了将ANGLE的Parsortix系统用于CTC捕获与Portrait+ CTC染色试剂盒用于CTC检测和表型特征化的结合效用。该工作流程提供了一种高效、标准化的解决方案,用于多种CTC表型(上皮、间充质及转变型)的特征化。

In a cohort of prostate cancer patients 64% of patients were positive for CTCs, and CTC clusters, which have up to 100 times increased metastatic potential, were found in 67% of the CTC positive samples. Patients with only mesenchymal CTCs accounted for 77% of the CTC positive patients, and no patients had only epithelial CTCs. This highlights the importance and value of using an epitope-independent CTC enrichment system, such as the Parsortix system.

在一组前列腺癌患者中,64%的患者对CTC呈阳性,CTC簇则在67%的CTC阳性样本中被发现,其转移潜力高达100倍。仅有间充质CTC的患者占CTC阳性患者的77%,没有患者仅有上皮CTC。这突显了使用表位独立的CTC富集系统(如Parsortix系统)的重要性和价值。

This study also demonstrates the potential utility of this workflow for longitudinal patient monitoring, where changes in CTC number (including their absence) and phenotype are associated with patient status. The study presented two case studies of metastatic prostate cancer patients with CTC results preceding a change in patient clinical status over time.

本研究还展示了该工作流程在长期患者监测中的潜在实用性,其中CTC数量(包括其缺失)和表型的变化与患者状态相关。研究展示了两例转移性前列腺癌患者的案例研究,CTC结果在患者临床状态变化之前。

2. Enhancing Multiplexing Capabilities in Digital PCR for Circulating Tumour Cell Analysis Using Amplitude-Based methodology

2. 在数字PCR中增强用于循环肿瘤细胞分析的多重检测能力,采用基于幅度的方法。

Molecular characterisation of CTCs is particularly important in the metastatic disease setting, where tissue biopsies may not be possible or repeatable, and there is a need for real-time tumour analysis and longitudinal monitoring of disease progression and treatment response. Recent advances in digital PCR (dPCR) technology, combined with multiplexing capabilities, have enhanced the ability to perform precise molecular characterisation from even a small number of CTCs.

在转移性疾病环境中,CTC的分子特征化尤为重要,因为组织活检可能不可行或无法重复,并且需要实时肿瘤分析以及对疾病进展和治疗反应的长期监测。最近在数字PCR(dPCR)科技方面的进展,结合多重检测能力,增强了从少量CTC中进行精准分子特征化的能力。

This proof-of-concept study demonstrates that using amplitude-based multiplexing with QIAGEN's Qiacuity dPCR system can increase the number of genes that can be assessed simultaneously in a Parsortix-enriched CTC sample. This method of molecular characterisation improves the ability to report a wider range of genetic markers from a single sample with the potential to provide a more comprehensive view into tumour biology.

本概念验证研究表明,使用QIAGEN的Qiacuity dPCR系统与基于幅度的多重检测相结合,可以增加在Passertrix富集的CTC样本中可以同时评估的基因数量。这种分子特征化的方法提高了从单个样本报告更广泛遗传标记的能力,有可能提供对肿瘤生物学更全面的视图。

Chief Scientific Officer, Karen Miller, commented:
"We are pleased to have presented two posters at the EACR Liquid Biopsies Conference. The results of these studies further demonstrate the utility of ANGLE's technology for capturing and characterising CTCs at both the cellular and molecular level. Advances in molecular characterisation will be key to building a comprehensive picture of cancer and providing insight during targeted drug discovery and development. We are continuing to develop Parsortix-based molecular assays to provide a range of highly sensitive and specific assays to serve the needs of our pharma customers."

首席科学官Karen Miller发表评论:
“我们很高兴在EACR液体活检会议上展示了两张海报。这些研究的结果进一步展示了ANGLE的科技在细胞和分子水平上捕获和特征化CTC的实用性。分子特征化的进展将是构建癌症全面图景的关键,并为靶向药物发现与开发提供见解。我们将继续开发基于Passertix的分子检测,以提供一系列高灵敏度和特异性的检测,以满足我们的制药客户的需求。”

The posters are available for review at:

海报可在以下位置查看:

For further information:

进一步了解:

ANGLE plc
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director

+44 (0) 1483 343434

Berenberg (NOMAD and Broker)
Toby Flaux, Ciaran Walsh, Milo Bonser

+44 (0) 20 3207 7800

FTI Consulting
Simon Conway, Ciara Martin
Matthew Ventimiglia (US)


+44 (0) 203 727 1000
+1 (212) 850 5624

ANGLE plc
Andrew Newland,首席执行官
Ian Griffiths,财务总监

+44(0)1483 343434

Berenberg(NOMAD和经纪人)
Toby Flaux,Ciaran Walsh,Milo Bonser

+44(0)20 3207 7800

fti咨询
Simon Conway,Ciara Martin
Matthew Ventimiglia(美国)


+44(0)203 727 1000
+1(212)850 5624

For Research Use Only. Not for use in diagnostic procedures.

仅用于研究。不能用于诊断程序。

For Frequently Used Terms, please see the Company's website on

有关常用术语,请参阅该公司网站,网址为

About ANGLE plc

关于ANGLE Plc

ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected CTC harvesting technology known as the Parsortix PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.

ANGLE是一家世界领先的液体活检公司,提供创新的循环肿瘤细胞(CTC)解决方案,用于研究、药物开发和临床肿瘤学,仅需一次简单的血液样本。ANGLE的经FDA认可并受专利保护的CTC捕获技术,即Parsortix PC1系统,能够对样本进行完整的下游分析,包括整个细胞成像和蛋白质组分析,以及全基因组和转录组分子分析。

ANGLE's commercial businesses are focusing on clinical services and diagnostic products. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma. Products include the Parsortix system, associated consumables and assays.

ANGLE的商业业务专注于临床服务和诊断产品。临床服务业务通过ANGLE的GCLP合规实验室提供。服务包括定制的检测开发和制药公司的临床试验测试。产品包括Parsortix系统、相关消耗品和检测。

Over 100 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit

超过100篇同行评议出版物证明了Parsortix系统的性能。要获取更多信息,请访问

Any reference to regulatory authorisations such as FDA clearance, CE marking or UK MHRA registration shall be read in conjunction with the full intended use of the product:

任何涉及FDA批准、CE标记或英国MHRA注册等监管授权的参考,应与产品的完整预期使用一起阅读:

The Parsortix PC1 system is an in vitro diagnostic device intended to enrich circulating tumor cells (CTCs) from peripheral blood collected in K2EDTA tubes from patients diagnosed with metastatic breast cancer. The system employs a microfluidic chamber (a Parsortix cell separation cassette) to capture cells of a certain size and deformability from the population of cells present in blood. The cells retained in the cassette are harvested by the Parsortix PC1 system for use in subsequent downstream assays. The end user is responsible for the validation of any downstream assay. The standalone device, as indicated, does not identify, enumerate or characterize CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs, including monitoring indications or as an aid in any disease management and/or treatment decisions.

Parsortix PC1系统是一种体外诊断设备,旨在从诊断为转移性乳腺癌患者采集的K2EDTA管中的外周血中富集循环肿瘤细胞(CTCs)。该系统采用微流控室(Parsortix细胞分离盒)捕获一定大小和可变形性的细胞,从血液中的细胞群中。留在盒中的细胞由Parsortix PC1系统收集,用于随后的下游分析。最终用户负责对任何下游分析进行验证。如指示的独立设备,不识别、计数或表征CTCs,并且不能用于为CTCs作出任何诊断/预后声明,包括监测指标或作为任何疾病管理和/或治疗决策的辅助。

All results reported in this announcement and any other products and services are for research use only and not for use in diagnostic procedures.

该公告中所报告的所有结果以及任何其他产品和服务仅供研究使用,不得用于诊断程序。

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit .

此信息由伦敦证券交易所的新闻发布非监管分发服务Reach提供。可能适用于使用和分发此信息的条款和条件。如需更多信息,请联系rns@lseg.com或访问。

SOURCE: ANGLE plc

来源:ANGLE plc


声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发